Bicycle Therapeutics' reported revenue is highly irregular, swinging from $887.0K in 2026Q1 to $34.1M in 2026Q3, which suggests the recent 190.2% growth may reflect a single collaboration event rather than a durable commercial trajectory.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | -$0.15+50.0% vs -$0.30 | $34M+178.7% vs $12M |
Q3 2026 Jul 30, 2026 | -$0.72-27.6% vs -$0.56 | $629,000-85.1% vs $4M |
Q2 2026 Apr 30, 2026 | -$0.87-67.3% vs -$0.52 | $887,000-88.2% vs $8M |
Q2 2026 Mar 17, 2026 | -$0.29+69.1% vs -$0.94 | $48M+581.6% vs $7M |
Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ: BCYC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the ten brokerages that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy
Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Analyst Ratings This is a breakdown of recent
Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) and Intellia Therapeutics (NASDAQ: NTLA - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Institutional and Insider Ownership 86.2% of Bicycle
Benchmark BCYC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Bicycle Therapeutics plc (BCYC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.61 | $250.51M | -1.78 | 105.77% | -169.75% | -26.02% | — | |
| $2.47 | $170.85M | -2.38 | — | — | -51.01% | — | |
| $31.05 | $18.86M | -2.81 | 3.7% | -353% | -87.96% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $29.41 | $1.75B | -4.71 | 48.03% | -264.76% | -34.63% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — |
Bicycle Therapeutics plc (BCYC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Bicycle Therapeutics plc (BCYC) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Jul 30, 2026·SEC
Jun 18, 2026·SEC
Get notified when BCYC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Bicycle Therapeutics plc (BCYC) stock FAQ — growth, dividends, profitability & financials explained
Bicycle Therapeutics plc (BCYC) reported $83.5M in revenue over the trailing twelve months. Revenue was $72.6M in fiscal year 2025.
Bicycle Therapeutics plc (BCYC) grew revenue by 194.7% over the trailing twelve months, compared with the twelve months before.
No. Bicycle Therapeutics plc (BCYC) reported a net loss of $141.8M over the trailing twelve months.
Bicycle Therapeutics plc (BCYC) had a return on equity (ROE) of -26.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Bicycle Therapeutics plc (BCYC) had negative free cash flow of $174.4M over the trailing twelve months.
